On the other hand, the injection of GCSF into the AML-treated group (AML+GCSF) did not affect the percentage of tubules with more than 15 CREM-stained cells compared to AML-alone (AML) 2 weeks post-treatment (Figure 6B), while it decreased the RNA expression level of Crem in (AML+GCSF)-treated group compared to AML-alone (AML) 2 weeks post-treatment (Figure 6B). This evidence concerns the gene CREM and acute myeloid leukemia.